Foreign Listings on U.S. Exchanges

Depending on your country’s regulatory frameworks, navigating U.S. securities laws can be a big hurdle. Doing the work to become compliant can require new systems, extensive internal audits, and new types of expertise outside of your current staffing. You’ll also need to overcome currency differences and cultural shifts as well.

Centri can guide you through all of these complexities and also help you find the most efficient path forward. That way you don’t lose unnecessary time and money as you work on becoming a foreign private issuer.

Entering into the U.S. exchanges can be a costly endeavor and you don’t want it to take away from clinical trial funding or intellectual property protections you need to stay competitive. Plus, your company will need to adhere to new requirements, like stringent FDA guidelines for drug and medical device approval. And you’ll need to learn the cultural nuances of the healthcare market in the U.S. to set yourself up for success.

With Centri’s help though, you don’t have to face it alone. Instead, you can leverage our experience in the life sciences industry and lean on our technical and up-to-date understanding of the latest requirements and regulations. Our team will guide you and ensure you’re prepared as you take these important steps toward a foreign listing.